BMS-Tempus, Roche-Zymeworks, and LGM-Sannova deals show what AI data, trispecifics, and nitrosamine testing mean for CMC, QA, and development teams.
News|Articles|December 2, 2001
- Pharmaceutical Technology-12-02-2001
- Volume 25
- Issue 12
Outsourcing Outlook
Author(s)Jim Miller
Capacity is a pivotal commodity in the contract manufacturing business. If you have enough of the right kind of capacity, it's like platinum; conversely, too much of the wrong kind of capacity is like tin.
Advertisement
Articles in this issue
almost 25 years ago
Bioterrorism Threat Shines Spotlight on Drug Manufacturingalmost 25 years ago
E-Sourcing: Internet Facilitates Flexible Collaborationalmost 25 years ago
International Employment Survey 2001almost 25 years ago
A Comprehensive Approach to Pharmaceutical Engineering TrainingAdvertisement
Related to this article
Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Advertisement
Advertisement